752202-08-7

Basic information

• Product Name: 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride
• Synonyms: 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride
• CAS NO: 752202-08-7
• Molecular Weight: 281.782
• Mol File: 752202-08-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride(752202-08-7)
• EPA Substance Registry System: 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride(752202-08-7)

Safety Data

• Hazardous Substances Data: 752202-08-7(Hazardous Substances Data)

Upstream product

• 75912-94-6 4-(3-chloropropoxy)benzoic acid ethyl ester 
• 685565-08-6 ethyl 4-(3-piperidin-1-ylpropoxy)benzoate 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 69076-29-5 4-(3-chloropropoxy)benzoic acid methyl ester 
• 767286-87-3 4-(3-(piperidin-1-yl)propoxy)benzoic acid 
• 685565-09-7 4-(3-(piperidin-1-yl)propoxy)benzoic acid hydrochloride 

Downstream Products

• 685872-83-7 4-phenyl-9-[4-(3-piperidin-1-ylpropoxy)benzoyl]-1-oxa-4,9-diazaspiro-[5, 5]-undecan-3-one hydrochloride 
• 685872-81-5 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-(R,S)-2-phenylpyrrolidine hydrochloride 
• 1334335-21-5 C₁₇H₂₄N₂O₂ 
• 685565-58-6 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-4-fluoroisoindoline 
• 1116338-64-7 C₃₇H₄₅F₃N₄O₃S 
• 1116338-58-9 C₃₄H₄₀N₂O₂ 
• 685565-70-2 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]isoindoline 
• 685565-60-0 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-5-cyanoisoindoline 
• 685565-62-2 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-5-[(morpholin-4-yl)carbonyl]isoindoline 
• 685565-61-1 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-5-[(pyrrolidin-1-yl)carbonyl]isoindoline 
• 685565-57-5 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-7-cyano-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 685565-42-8 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]indole 
• 685565-39-3 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]indoline 

Relevant articles and documents

Novel and highly potent histamine H3 receptor ligands. Part 1: Withdrawing of hERG activity

Pre-clinical investigation of some aryl-piperidinyl ether histamine H3 receptor antagonists revealed a strong hERG binding. To overcome this issue, we have developed a QSAR model specially dedicated to H3 receptor ligands. This model was designed to be di

BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES

The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.